AttendMe Owl Logo
AttendMe
Evidence Evolution
PathologyPathology

How This Evidence Evolved

HER2 Classification Evolution

From binary positive/negative to the HER2-low paradigm shift

15.1

Timeline

Signal

Early observations and pilot data that first suggested a new direction

HER2 gene amplification linked molecular testing to breast-cancer prognosis. In a study of 189 primary breast cancers, HER2/neu was amplified in 30% of tumors and predicted overall survival and time to relapse, including after adjustment for other prognostic factors. Testing then became relevant to treatment selection. ASCO/CAP described both IHC protein-expression scores and FISH gene-amplification measures, with additional action required for equivocal results. Its testing guideline did not establish one method as clearly superior for predicting benefit from anti-HER2 therapy.
Proof

Landmark RCTs and pivotal trials that established the evidence base

ASCO/CAP recommendations sought to standardize HER2 testing: approximately 20% could be inaccurate, and HER2 status should be determined for all invasive breast cancers. In HERA, 1 year of trastuzumab after adjuvant chemotherapy improved disease-free survival; interim overall survival was not significantly different. BCIRG-006 provided distinct survival evidence: estimated 5-year overall survival was 87% with AC-T, 92% with AC-T plus trastuzumab and 91% with TCH. Both trastuzumab regimens were superior to AC-T; heart failure and cardiac dysfunction were more frequent with AC-T plus trastuzumab than TCH.
Extension

Follow-up studies, subgroup analyses, and real-world validation

DESTINY-Breast04 established benefit from trastuzumab deruxtecan in previously treated HER2-low metastatic breast cancer. Across all randomized patients, median progression-free survival was 9.9 versus 5.1 months and overall survival was 23.4 versus 16.8 months with physician-choice chemotherapy. DESTINY-Breast06 later studied hormone receptor-positive disease after endocrine therapy, including HER2-low and exploratory HER2-ultralow groups. Median progression-free survival in HER2-low disease was 13.2 versus 8.1 months, with consistent exploratory ultralow results. ASCO/CAP affirmed existing testing recommendations rather than creating a new HER2-low result category.
Guidelines

Integration into clinical practice guidelines and recommendations

The ASCO/CAP update explains why distinguishing IHC 0 from 1+ became clinically relevant through trial-entry criteria.
ASCO/CAP HER2 Testing Update
Now

Current standard of care and ongoing research directions

Low HER2 expression raises a practical scoring question. The 2023 ASCO/CAP update noted that DESTINY-Breast04 excluded IHC 0 tumors and that the IHC 0-versus-1+ threshold was clinically relevant because of the trial criteria supporting regulatory approval. It did not regard that threshold as an established biological or predictive boundary and considered new reporting categories premature. Reproducible scoring and clear reporting therefore matter when applying treatment evidence.

Landmark Trials in This Story

Science (New York, N.Y.) 1987Landmark

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Correlation of HER2 amplification with relapse and survival

Science (New York, N.Y.)CohortN=189
ASCO/CAP Guidelines2007Landmark

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

Standardized HER2 testing criteria

Journal of clinical oncology : official journal of the American Society of Clinical OncologyPractice guideline
HERA2005Landmark

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

Disease-free survival

New England journal of medicineRCT
BCIRG-0062011

Adjuvant trastuzumab in HER2-positive breast cancer.

Disease-free survival at 5 years: AC-T 75%, AC-T plus trastuzumab 84%, TCH 81%

The New England journal of medicineRandomized controlled trialN=3,222
DESTINY-Breast042022

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

PFS in all patients: trastuzumab deruxtecan 9.9 vs chemotherapy 5.1 months (HR 0.50, P<0.001)

The New England journal of medicineRandomized phase 3 trialN=557
DESTINY-Breast062024

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

PFS in HER2-low disease: trastuzumab deruxtecan 13.2 vs chemotherapy 8.1 months (HR 0.62, 95% CI 0.52–0.75)

The New England journal of medicineRandomized phase 3 trialN=866
AI-assisted HER2 scoring2026

Artificial Intelligence (AI)-Assisted Human Epidermal Growth Factor Receptor 2 (HER2) Scoring in Breast Cancer: Diagnostic Agreement and Understanding Discordance.

Reader agreement at slide review: without AI 79.8% vs with AI 88.6% (95% CIs 77.9–81.7 and 86.9–90.1)

Laboratory investigation; a journal of technical methods and pathologyRetrospective single-center diagnostic studyN=581

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

What is HER2-low and why does it matter?+
HER2-low in DESTINY-Breast04 meant IHC 1+ or IHC 2+ with negative in situ hybridization. Trastuzumab deruxtecan improved progression-free and overall survival compared with chemotherapy in previously treated metastatic disease. ASCO/CAP recognized the treatment relevance of IHC 0 versus 1+ while affirming existing reporting recommendations.
Why is distinguishing IHC 0 from IHC 1+ so challenging for pathologists?+
ASCO/CAP describes IHC 0 versus 1+ differences as often subtle and now clinically relevant because of trial eligibility criteria. The update affirms prior HER2 reporting recommendations and provides best-practice guidance for distinguishing these results. It states that evidence does not support a new IHC 0 versus 1+ prognostic or predictive threshold for response.
How might AI and digital pathology improve HER2 scoring?+
In a retrospective single-center study, 853 HER2 IHC whole-slide images from 581 patients were scored with and without AI assistance. Overall reader agreement increased from 79.8% to 88.6%. The system supplied categorical scores and quantitative cell-level staining metrics. These findings support reader consistency; they do not establish a treatment benefit.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026